A systematic review of dydrogesterone for the treatment of threatened miscarriage

Howard Carp*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


The objective of this systematic review was to assess whether the orally acting progestagen, dydrogesterone lowers the incidence of miscarriage in women with threatened miscarriage. A computerized search was performed in Medline, Embase, and Ovid Medline for original reports with the product name 'Duphaston' or 'dydrogesterone', and limited to clinical human data. Twenty-one reports of dydrogesterone treatment were identified with 1380 patients. Five randomized trials were identified, including 660 women who fulfilled the criteria for metaanalysis. The number of subsequent miscarriages or continuing pregnancies per randomized woman was compared in women receiving dydrogesterone compared to standard bed rest or placebo intervention. There was a 13% (44/335) miscarriage rate after dydrogesterone administration compared to 24% in control women [odds ratio for miscarriage 0.47, (CI = 0.31-0.7), 11% absolute reduction in the miscarriage rate]. The adverse and side effects were summarized in all 21 reports, and seemed to be minimal. Although all the predictive and confounding factors could not be controlled for, the results of this systematic review show a significant reduction of 47% in the odds for miscarriage when dydrogesterone is compared to standard care indicating a real treatment effect.

Original languageEnglish
Pages (from-to)983-990
Number of pages8
JournalGynecological Endocrinology
Issue number12
StatePublished - Dec 2012


FundersFunder number
Abbott Products Operations AG


    • Abortion
    • Duphaston
    • Dydrogesterone
    • Miscarriage
    • Progesterone
    • Threatened miscarriage


    Dive into the research topics of 'A systematic review of dydrogesterone for the treatment of threatened miscarriage'. Together they form a unique fingerprint.

    Cite this